Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

This study is collecting real-world safety information about upadacitinib (brand name Rinvoq), a medication used to treat inflammatory conditions like rheumatoid arthritis, ulcerative colitis, and others, by following patients who are newly prescribed it in clinical practice. **You may be eligible if...** - You are 18 or older and have been prescribed Rinvoq (upadacitinib) starting from January 1, 2024 - You are willing to participate and can be contacted by phone - You do not have significant cognitive impairment **You may NOT be eligible if...** - You have cognitive impairment that prevents you from answering phone questionnaires - You are currently participating in a Phase I, II, or III clinical trial - Your life expectancy is less than 1 month - You do not have a valid phone contact Talk to your doctor to see if this trial is right for you.